How China plans to ‘firmly rank at the global forefront’ with 25% of first-in-class drugs
China has set its sights on becoming a global biomedicine powerhouse by 2030, targeting key technological breakthroughs and at least a quarter of the world’s first-in-class drugs market under a new five-year plan for the sector. By the end of the decade, China would “firmly rank at the global forefront” in biopharmaceutical research and development and applications, with its “core…
China aims to solidify its position as a leader in global biomedicine by 2030, with a new five-year plan targeting key technological advancements and a 25% share in the world's first-in-class drugs market. This ambitious plan, released jointly by eight government agencies, aims to elevate China's core competitiveness and international influence in the pharmaceutical sector.
The biomedical industry is envisioned as a pillar for the nation, with specific targets set for pharmaceutical revenue and the creation of drug manufacturers. The innovative drugs market is projected to grow at an annual rate of more than 20%, with at least five products generating global sales above US$1 billion. Chinese first-in-class innovative drugs are expected to account for at least a quarter of the global total.
These targets exceed those set in the previous 14th five-year plan, which lacked quantifiable indicators for innovative drugs. The plan emphasizes the need for breakthroughs in core technologies across critical fields, such as cell and gene therapy, green manufacturing, big data, and synthetic biotechnology. Artificial intelligence, quantum computing, and supercomputing are also slated for expansion in pharmaceutical R&D, alongside frontier technologies like gene editing and brain-computer interfaces.
The plan outlines several critical areas requiring breakthroughs, including artificial life system synthesis, organoids, organ-on-a-chip, and universal cell therapies.
Written by urgent.news from South China Morning Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
